NOVELTY - Preparing amorphous fluvastatin sodium, comprises: dissolution of tert-butyl ester of fluvastatin in a mixture of toluene and methanol; addition of aqueous solution of sodium hydroxide (NaOH); phase separation of reaction mass; concentration of the combined aqueous layers; filtration of suspended precipitated solid; dissolution of the solid in tetrahydrofuran (THF), filtration through e.g. Celite (RTM: Diatomaceous earth) and addition of cyclohexane to clear THF solution; filtration and washing of the obtained solid with cyclohexane; and dissolution of the obtained wet cake in methanol, filtration and spray drying.    USE - The process is useful for preparing amorphous fluvastatin sodium (claimed), which is useful for treating hypercholesterolemia and hyperlipoproteinemia, and preventing coronary heart disease. No biological data given.    ADVANTAGE - The process is a one-pot process. The process provides fluvastatin and its salts in high yield and high purity. The amorphous fluvastatin sodium is stable. The process is a cost-effective and environmental friendly.    DETAILED DESCRIPTION - Preparing amorphous fluvastatin sodium, comprises: (a) dissolution of 1,1-dimethylethyl (3R,5S,6E)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoate (tert-butyl ester of fluvastatin), in a mixture of toluene and methanol; (b) addition of aqueous solution of sodium hydroxide (NaOH) into the obtained solution; (c) phase separation of the reaction mass; (d) concentration of the combined aqueous layers to obtain an aqueous suspension; (e) filtration of the suspended precipitated solid and wash with water to obtain a thick paste; (f) dissolution of the solid in tetrahydrofuran (THF), filtration through Celite (RTM: Diatomaceous earth) or cartridge filter and addition of cyclohexane to the clear THF solution and stir the precipitated product for approximately three hours and cool down gradually to 25-30 degrees C; (g) filtration and washing of the obtained solid with cyclohexane; and (h) dissolution of the obtained wet cake in methanol, filtration and spray drying. INDEPENDENT CLAIMS are included for amorphous fluvastatin sodium obtained by the process having purity of higher than 99.9% and anti-isomers of less than 0.5%, preferably less than 0.1%.